nach oben

Current Diabetes Reports

Erschienen in:

01.11.2018 | Therapies and New Technologies in the Treatment of Diabetes (M Pietropaolo, Section Editor)

Metabolic Surgery as a Treatment Option for Type 2 Diabetes Mellitus: Surgical View

verfasst von: Eric Rachlin, Carlos Galvani

Erschienen in: Current Diabetes Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Type 2 diabetes mellitus (T2DM) is increasing in prevalence and associated with numerous metabolic complications leading to increased mortality and costs. Metabolic surgery, or surgery to treat T2DM and obesity, is effective at achieving remission from T2DM. This review discusses the most commonly used surgical options including the adjustable gastric band, the Roux-en-Y gastric bypass, the sleeve gastrectomy, and the biliopancreatic diversion with duodenal switch and their ability to treat and prevent T2DM.

Recent Findings

There is an increasing body of literature that justifies the inclusion of metabolic surgery into the treatment algorithm for patients with obesity and T2DM. Metabolic procedures should be performed at centers that offer comprehensive treatment of metabolic disorders and have expertise in gastrointestinal surgery. The incremental improvement in the quality and safety of metabolic surgery has significantly reduced the risk of serious post-operative complications.

Summary

Metabolic surgery is a safe and effective treatment option for obese patients with T2DM.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. https://doi.org/10.2337/dci18-0007.CrossRefPubMedCentral

Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in Diabetes among adults in the United States, 1988-2012. JAMA. 2015;314(10):1021–9. https://doi.org/10.1001/jama.2015.10029.CrossRefPubMed

Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–209.CrossRefPubMed

Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138–45.CrossRefPubMed

Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–9.CrossRefPubMed

Hage MP, Safadi B, Salti I, Nasrallah M. Role of gut-related peptides and other Hormones in the amelioration of type 2 diabetes after Roux-En-Y gastric bypass surgery. ISRN Endocrinol. 2012;2012:504756. https://doi.org/10.5402/2012/504756.CrossRefPubMedPubMedCentral

Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411. https://doi.org/10.1146/annurev.med.051308.105148.CrossRefPubMed

Guo Y, Huang ZP, Liu CQ, Qi L, Sheng Y, Zou DJ. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol. 2018;178(1):43–56. https://doi.org/10.1530/EJE-17-0403.CrossRefPubMed

Peat CM, Kleiman SC, Bulik CM, Carroll IM. The intestinal microbiome in bariatric surgery patients. Eur Eat Disord Rev. 2015;23(6):496–503. https://doi.org/10.1002/erv.2400.CrossRefPubMedPubMedCentral

10.

Daigle CR, Brethauer SA, Tu C, Petrick AT, Morton JM, Schauer PR, et al. Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes. Surg Obes Relat Dis. 2018;14(5):652–7. https://doi.org/10.1016/j.soard.2018.01.008.CrossRefPubMed

11.

Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-7, 1991. Nutrition 1996;12(6):397–404

12.

Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Delegates of the 2nd Diabetes Surgery Summit metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77. https://doi.org/10.2337/dc16-0236.CrossRefPubMed

13.

Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, MM MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21(Suppl 1):S1–27. https://doi.org/10.1002/oby.20461.CrossRef

14.

Edholm D, Kullberg J, Karlsson FA, Haenni A, Ahlström H, Sundbom M. Changes in liver volume and body composition during 4 weeks of low calorie diet before laparoscopic gastric bypass. Surg Obes Relat Dis. 2015;11(3):602–6. https://doi.org/10.1016/j.soard.2014.07.018.CrossRefPubMed

15.

Aberle J, Freier A, Busch P, Mommsen N, Beil FU, Dannheim V, et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes Surg. 2009;19(11):1504–7. https://doi.org/10.1007/s11695-009-9940-5.CrossRefPubMed

16.

Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017;13(5):727–41. https://doi.org/10.1016/j.soard.2016.12.018.CrossRefPubMed

17.

O'Brien PE, MacDonald L, Anderson M, Brennan L, Brown WA. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87–94. https://doi.org/10.1097/SLA.0b013e31827b6c02.CrossRefPubMed

18.

Fielding GA, Allen JW. A step-by-step guide to placement of the LAP-BAND adjustable gastric banding system. Am J Surg. 2002;184(6B):26S–30S.CrossRefPubMed

19.

Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87. https://doi.org/10.1001/jamasurg.2013.3654.CrossRefPubMedPubMedCentral

20.

Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, et al. Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA Surg. 2015;150(10):931–40. https://doi.org/10.1001/jamasurg.2015.1534.CrossRefPubMedPubMedCentral

21.

Altieri MS, Yang J, Telem DA, Meng Z, Frenkel C, Halbert C, et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc. 2016;30(5):1725–32. https://doi.org/10.1007/s00464-015-4402-8.CrossRefPubMed

22.

Victorzon M, Tolonen P. Mean fourteen-year, 100% follow-up of laparoscopic adjustable gastric banding for morbid obesity. Surg Obes Relat Dis. 2013;9(5):753–7. https://doi.org/10.1016/j.soard.2013.05.010.CrossRefPubMed

23.

Benotti P, Wood GC, Winegar DA, Petrick AT, Still CD, Argyropoulos G, et al. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg. 2014;259(1):123–30. https://doi.org/10.1097/SLA.0b013e31828a0ee4.CrossRefPubMed

24.

El-Kadre L, Tinoco AC, Tinoco RC, Aguiar L, Santos T. Overcoming the learning curve of laparoscopic Roux-en-Y gastric bypass: a 12-year experience. Surg Obes Relat Dis. 2013;9(6):867–72. https://doi.org/10.1016/j.soard.2013.01.020.CrossRefPubMed

25.

Rodríguez A, Mosti M, Sierra M, Pérez-Johnson R, Flores S, Dominguez G, et al. Small bowel obstruction after antecolic and antegastric laparoscopic Roux-en-Y gastric bypass: could the incidence be reduced? Obes Surg. 2010;20(10):1380–4. https://doi.org/10.1007/s11695-010-0164-5.CrossRefPubMed

26.

Yan Y, Sha Y, Yao G, Wang S, Kong F, Liu H, et al. Roux-en-Y Gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(17):e3462. https://doi.org/10.1097/MD.0000000000003462.CrossRef

27.

•• Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55. https://doi.org/10.1056/NEJMoa1700459. This study demonstrates one of the longest follow-up periods, 12 years, for patients undergoing metabolic surgery. It demonstrates the long-term efficacy of metabolic surgery in achieving weight loss and decrease in obesity-associated comorbidities. CrossRefPubMedPubMedCentral

28.

• Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, et al. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016;151(11):1046–55. https://doi.org/10.1001/jamasurg.2016.2317. This prospective cohort study shows the durability of weight loss with metabolic surgery over time. CrossRefPubMedPubMedCentral

29.

•• Kabir A, Mousavi S, Pazouki A. The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A systematic Review and Meta-Analysis. Curr Diabetes Rev. 2018 . https://doi.org/10.2174/1573399814666180403164529. This review looks at complication rates of various metabolic procedures.

30.

Wendling MR, Linn JG, Keplinger KM, Mikami DJ, Perry KA, Melvin WS, et al. Omental patch repair effectively treats perforated marginal ulcer following Roux-en-Y gastric bypass. Surg Endosc. 2013;27(2):384–9.CrossRefPubMed

31.

Moon RC, Teixeira AF, Goldbach M, Jawad MA. Management and treatment outcomes of marginal ulcers after Roux-en-Y gastric bypass at a single high volume bariatric center. Surg Obes Relat Dis. 2014;10(2):229–34. https://doi.org/10.1016/j.soard.2013.10.002.CrossRefPubMed

32.

Estimate of bariatric surgery numbers, 2011–2017. American Society for Metabolic and Bariatric Surgery, asmbs.org/resources/estimate-of-bariatric-surgery-numbers.

33.

Mans E, Serra-Prat M, Palomera E, Suñol X, Clavé P. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102(3):540–7. https://doi.org/10.3945/ajcn.114.104307.CrossRefPubMed

34.

Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52. https://doi.org/10.1007/s11695-013-1066-0.CrossRefPubMed

35.

Stenard F, Iannelli A. Laparoscopic sleeve gastrectomy and gastroesophageal reflux. World J Gastroenterol. 2015;21(36):10348–57. https://doi.org/10.3748/wjg.v21.i36.10348.CrossRefPubMedPubMedCentral

36.

Kim M, Navarro F, Eruchalu CN, Augenstein VA, Heniford BT, Stefanidis D. Minimally invasive Roux-en-Y gastric bypass for fundoplication failure offers excellent gastroesophageal reflux control. Am Surg. 2014;80(7):696–703.PubMed

37.

Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Thiesen V, Fornari F. The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the Montreal Consensus. Ann Surg. 2010;251(2):244–8. https://doi.org/10.1097/SLA.0b013e3181bdff20.CrossRefPubMed

38.

•• Peterli R, Wölnerhanssen BK, Vetter D, Nett P, Gass M, Borbély Y, et al. Laparoscopic sleeve gastrectomy versus Roux-Y-gastric bypass for morbid obesity-3-year outcomes of the prospective randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg. 2017;265(3):466–73. https://doi.org/10.1097/SLA.0000000000001929. A randomized controlled trial comparing RYGB and SG over a 3 year period. CrossRefPubMed

39.

•• Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51. https://doi.org/10.1056/NEJMoa1600869. A randomized controlled trial comparing medical management to RYGB to SG over a 5 year period. CrossRefPubMedPubMedCentral

40.

Arterburn DE, Olsen MK, Smith VA, Livingston EH, Van Scoyoc L, Yancy WS Jr, et al. Association between bariatric surgery and long-term survival. JAMA. 2015;313(1):62–70. https://doi.org/10.1001/jama.2014.16968.CrossRefPubMed

41.

Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. https://doi.org/10.1001/jama.2014.5988.CrossRefPubMed

42.

Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36; discussion 636-7. https://doi.org/10.1097/SLA.0b013e3182a5034b.CrossRefPubMed

43.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76. https://doi.org/10.1056/NEJMoa1200225.CrossRefPubMedPubMedCentral

44.

Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170–80. https://doi.org/10.1016/j.soard.2016.08.011.CrossRefPubMed

45.

•• Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS Randomized Clinical Trial. JAMA. 2018;319(3):241–54. https://doi.org/10.1001/jama.2017.20313. A randomized controlled trial comparing SG and RYGB over a 5-year period. CrossRefPubMedPubMedCentral

46.

•• Melissas J, Stavroulakis K, Tzikoulis V, Peristeri A, Papadakis JA, Pazouki A, et al. Sleeve gastrectomy vs Roux-en-Y gastric bypass. Data from IFSO-European Chapter Center of Excellence Program. Obes Surg. 2017;27(4):847–55. https://doi.org/10.1007/s11695-016-2395-6. A large cohort study comparing SG and RYGB. CrossRefPubMed

47.

• Risstad H, Søvik TT, Engström M, Aasheim ET, Fagerland MW, Olsén MF, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015;150(4):352–61. https://doi.org/10.1001/jamasurg.2014.3579.CrossRefPubMed

48.

Biertho L, Lebel S, Marceau S, Hould FS, Julien F, Biron S. Biliopancreatic diversion with duodenal switch: surgical technique and perioperative care. Surg Clin North Am. 2016;96(4):815–26. https://doi.org/10.1016/j.suc.2016.03.012.CrossRefPubMed

Titel: Metabolic Surgery as a Treatment Option for Type 2 Diabetes Mellitus: Surgical View
verfasst von: Eric Rachlin
Carlos Galvani
Publikationsdatum: 01.11.2018
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 11/2018
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-018-1094-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Metabolic Surgery as a Treatment Option for Type 2 Diabetes Mellitus: Surgical View

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Enteroviral Infections as a Trigger for Type 1 Diabetes

Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation

Advancing Measurement of Diabetes at the Population Level

The Role of Accessory Cells in Islet Homeostasis

Lifestyle Factors Affecting the Gut Microbiota’s Relationship with Type 1 Diabetes

Red Meat Consumption (Heme Iron Intake) and Risk for Diabetes and Comorbidities?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin